{"pmid":32438034,"title":"Does lopinavir really inhibit SARS-CoV-2?","text":["Does lopinavir really inhibit SARS-CoV-2?","Pharmacol Res","Cattaneo, Dario","Corbellino, Mario","Clementi, Emilio","Galli, Massimo","Riva, Agostino","Gervasoni, Cristina","32438034"],"journal":"Pharmacol Res","authors":["Cattaneo, Dario","Corbellino, Mario","Clementi, Emilio","Galli, Massimo","Riva, Agostino","Gervasoni, Cristina"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438034","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104898","keywords":["ic50","sars-cov-2","lopinavir"],"e_drugs":["Lopinavir"],"topics":["Treatment"],"weight":1,"_version_":1667521393675206657,"score":9.490897,"similar":[{"pmid":32251767,"pmcid":"PMC7127386","title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","text":["Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.","Antiviral Res","Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling","32251767"],"abstract":["An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits."],"journal":"Antiviral Res","authors":["Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251767","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104786","keywords":["abstract","covid-19","emetine","homoharringtonine","lopinavir","remdesivir","ritonavir"],"e_drugs":["remdesivir","Ribavirin","Lopinavir","Emetine","favipiravir","Homoharringtonine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490993115138,"score":70.31308},{"pmid":32462970,"title":"Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","text":["Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge.","J Biomol Struct Dyn","Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra","32462970"],"abstract":["SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge."],"journal":"J Biomol Struct Dyn","authors":["Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462970","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1775127","keywords":["binding affinity","drug repurposing","endonuclease","ic50","molecular dynamic simulation","sars-cov-2"],"e_drugs":["Amino Acids, Essential","Uridine Monophosphate","Ribonucleotides","glisoxepide","Idarubicin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521291567104,"score":58.907124},{"pmid":32473230,"title":"Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.","text":["Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.","No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection.","J Infect","Klement-Frutos, Elise","Burrel, Sonia","Peytavin, Gilles","Marot, Stephane","Le, Minh P","Godefroy, Nagisa","Calvez, Vincent","Marcelin, Anne-Genevieve","Caumes, Eric","Pourcher, Valerie","Boutolleau, David","32473230"],"abstract":["No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection."],"journal":"J Infect","authors":["Klement-Frutos, Elise","Burrel, Sonia","Peytavin, Gilles","Marot, Stephane","Le, Minh P","Godefroy, Nagisa","Calvez, Vincent","Marcelin, Anne-Genevieve","Caumes, Eric","Pourcher, Valerie","Boutolleau, David"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473230","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jinf.2020.05.039","keywords":["covid-19","sars-cov-2","lopinavir","pharmacology","protease inhibitor","virology"],"locations":["Ritonavir"],"topics":["Treatment"],"weight":1,"_version_":1668255193255378944,"score":53.725384},{"pmid":32297571,"title":"SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus","text":["SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus","Here we report on the most recent updates on experimental drugs successfully em- ployed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy- chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experi- mental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this vi- rus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies.","Curr Med Chem","Costanzo, Michele","De Giglio, Maria Anna Rachele","Roviello, Giovanni Nicola","32297571"],"abstract":["Here we report on the most recent updates on experimental drugs successfully em- ployed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy- chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experi- mental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this vi- rus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies."],"journal":"Curr Med Chem","authors":["Costanzo, Michele","De Giglio, Maria Anna Rachele","Roviello, Giovanni Nicola"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297571","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2174/0929867327666200416131117","keywords":["covid-19","coronavirus","antiviral drugs","hydroxychloroquine","lopinavir","remdesivir","ritonavir.","favipiravir","sars-cov-2"],"locations":["USA","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Oseltamivir","lopinavir-ritonavir drug combination","Chloroquine","Darunavir","favipiravir","arbidol"],"topics":["Treatment"],"weight":1,"_version_":1666138493210853377,"score":51.58833},{"pmid":32104907,"title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","text":["A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.","J Med Virol","Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang","32104907"],"abstract":["In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19."],"journal":"J Med Virol","authors":["Yao, Tian-Tian","Qian, Jian-Dan","Zhu, Wen-Yan","Wang, Yan","Wang, Gui-Qiang"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104907","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25729","keywords":["covid-19","mers","sars","coronavirus","lopinavir"],"locations":["Wuhan","vivo"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Lopinavir"],"topics":["Treatment"],"weight":1,"_version_":1666138492881600512,"score":49.373726}]}